Figure. Triple-pathway anti-tumor mechanisms of Chiauranib
- In June 2018, approvals for Phase II/III clinical trials of Chiauranib were granted by the CFDA. Phase II clinical trials of the drug for a variety of tumors have now been completed.
- In December 2020, Chiauranib was included in the “Breakthrough Therapy Category” for the treatment of small cell lung cancer by the Center for Drug Evaluation (CDE) of NMPA.
- In March 2021, Chiauranib was included in the “Breakthrough Therapy Category” for the treatment of ovarian cancer by the CDE of NMPA.
- In March 2021, an application for a pivotal Phase III clinical trial of Chiauranib in the treatment of small cell lung cancer was approved by the NMPA.
- In April 2021, an application for a pivotal Phase III clinical trial of Chiauranib in the treatment of ovarian cancer was approved by the NMPA.
- In April 2021, an investigational new drug (IND) application for a Phase Ib/II clinical trial of Chiauranib was approved by the FDA, the first approved trial indication for Chiauranib in the U.S.
- In May 2021, an application for the Phase II clinical trial of Chiauranib for triple-negative breast cancer was accepted by the NMPA.